Baricitinib treatment linked to reduced mortality in COVID-19 patients
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.“We are pleased to report a 71 percent reduction in mortality for the group receiving baricitinib in addition to standard care,” says Volker Lauschke , corresponding author and